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Tregalizumab (BT-061) increases regulatory T cell function
Boosting regulatory T-cell function with the humanized
CD4-speciﬁc humanized monoclonal antibody
Tregalizumab (BT-061)
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Regulatory T cells (Tregs) represent asubset of CD4+ T cells that express the
forkhead box protein 3 factor (FOXP3) in
their nuclei1 and the high-afﬁnity interleukin
2 (IL-2) receptor CD25 on their cell surface
as they are dependent on IL-2 for their
homeostasis.2 Since their discovery 20 years
ago,3 Tregs have proven to be indispensable
for maintaining immunological self-tolerance.
Indeed, Treg depletion results in a wide
spectrum of autoimmune manifestations,3
whereas mutations of FOXP3 lead to fatal
autoimmunity both in mice (scurfy mice)
and humans (Immune dysfunction, polyendo-
crinopathy, enteropathy, X-linked syndrome).1
Further, restoring the T-cell balance in favor of
Tregs has allowed the control of autoimmunity
in a number of animal rheumatologic models.4
On the basis of these preclinical data,
clinical trials aimed at boosting Tregs in order
to promote tolerance have been conducted in
the context of autoimmune diseases or allo-
geneic hematopoietic stem cell transplanta-
tion. Speciﬁcally, boosting Treg function by
administration of low doses of IL-2 has
shown promising activities in patients with
hepatitis C virus-induced vasculitis5 and in
those suffering from chronic graft-versus-
host-disease (a redoubtable complication of
allogeneic hematopoietic cell transplantation
caused by donor immune cells contained in
the graft reacting against recipient healthy
tissues that shares many clinical features with
autoimmune diseases).6,7 Further, recent stu-
dies have suggested that transfusion of fresh
or in vitro-expanded Tregs could prevent
graft-versus-host disease after allogeneic
hematopoietic cell transplantation8 or prevent
type 1 diabetes evolution.9 However, treat-
ment with low-dose IL-2 might be limited by
the observation that Treg number/function
return to baseline quickly after IL-2
discontinuation,7 whereas the administration
of sufﬁcient numbers of relatively pure Tregs
has remained technically challenging.
Over the last decades, there has been
substantial interests in the use of non-
depleting anti-CD4 antibodies for tolerance
induction.10 Although Treg activity has been
suggested to be the main mechanism of anti-
CD4-induced tolerance,10 recent data have
demonstrated that CD4 blockade induces
tolerance also in the absence of Tregs, by
attenuating the co-stimulatory signals.11
In the current issue of the journal, Helling
et al.12 report that, in contrast to other anti-
CD4 monoclonal antibodies, the humanized
non-depleting anti-CD4 monoclonal anti-
body tregalizumab (BT-061) selectively acti-
vates the suppressive properties of Tregs,
in vitro, by binding to a unique conforma-
tional epitope on the domain 2 of CD4.
Following binding to CD4, tregalizumab
induces a T-cell receptor (TCR) signaling
pathway that is incomplete and unique when
compared with OKT3 and other anti-CD4
antibodies, but that is similar in Treg and in
conventional CD4+ T cells. Speciﬁcally, in
comparison to what is observed with OKT3
or other anti-CD4 antibodies, tregalizumab
induces similar phosphorylation levels of Lck,
PLC-γ and SLP-76, but lower phosphoryla-
tion levels of SHP-2, ZAP70, LAT, MEK,
PyK2 and MAPK. In addition, in contrast to
what is observed with OKT3 and other anti-
CD4 antibodies, tregalizumab does not lead
to the phosphorylation of ItK, Akt, ERK,
JNK, PKC, IKK and NF-κB. Further, the
duration of phosphorylation induced by tre-
galizumab is signiﬁcantly shorter than what is
observed with OKT3 or other anti-CD4
antibodies. Given previous observations
demonstrating that a suboptimal mode of
T-cell activation leads to the generation of
Treg,1 it is likely that the speciﬁc incomplete
engagement of the TCR pathway by tregali-
zumab explains the enhanced Treg suppres-
sive function. This might also be in line with
the recent data demonstrating that TCR
signaling is essential for maintenance of Treg
immunoregulatory function.13
Interestingly, Treg activation by tregalizu-
mab was achieved without the modulation of
typical Treg activation markers such as CD25,
CD39, CTLA-4, GARP, LAG-3 or HLA-DR.
However, latency-associated peptide (LAP)
expression was upregulated by tregalizumab
(Figure 1). It is worth mentioning that cell
surface expression of LAP is associated with
increased TGF-β signaling and secretion.
Given than TGF-β is an important mechan-
ism of Treg inhibition, tregalizumab-induced
overexpression of LAP by Treg is probably
one of the mechanisms explaining the higher
inhibitory capacity of Treg when boosted
with tregalizumab. Indeed, the same group
of investigators recently observed that trega-
lizumab induces TGF-β secretion in addition
to increasing cycling adenosine monopho-
sphate levels, both selectively in Tregs.
Combined with previous observations that
human immunodeﬁciency virus-1 envelope
protein gp120 (a molecule that binds with a
high afﬁnity to domain 1 of human CD4) also
mediates Treg activation and prevents graft-
versus-host disease in humanized mice,14 the
current article by Helling et al.12 supports the
clinical use of CD4-mediated manipulation of
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Tregs for tolerance induction in patients with
autoimmune disease or with graft-versus-host
disease. Such a phase IIb clinical trial is
currently assessing the impact of tregalizumab
in combination with methotrexate in subjects
who have active rheumatoid arthritis, and an
inadequate response to methotrexate alone
(clinicaltrial.gov# NCT01999192). In sum-
mary, the study by Helling et al.12 provides
novel insights into the mechanism of action of
tregalizumab, a clinically relevant immuno-
modulatory antibody.
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Figure 1 Tregalizumab (BT-061) activates Treg in vitro. Tregalizumab binds the extracellular domain 2
(D2) of the CD4 molecule. Treg suppression activity is then enhanced, possibly through increased LAP
expression and increased secretion of TGF-β. Increases in Treg cycling adenosine monophosphate levels
following tregalizumab binding on CD4 have also been demonstrated by the same group of investigators
(Czeloth et al., manuscript submitted).
News and Commentary
2
Immunology and Cell Biology
